This article is an overview of the immunomodulatory effects of apheresis in renal diseases, especially primary and secondary glomerulonephritis, and the clinical evidence for the effi cacy of apheresis therapy. Permeability factor(s) derived from circulating T cells are speculated to have a crucial role in the proteinuria of nephrotic syndrome (NS). Plasma exchange (PE); immunoadsorption plasmapheresis (IAPP), using protein A sepharose cartridges; low-density lipoprotein apheresis; and lymphocytapheresis (LCAP) have been used to remove such factors or pathogenic T cells. Other glomerular diseases induced by specifi c antibodies such as anti-glomerular basement membrane antibodies, anti-neutrophil cytoplasmic antibodies, and immune-complexes have also been treated with PE, double-fi ltration plasmapheresis, IAPP, and LCAP. Recommendations, based on the evidence from recent randomized controlled studies, have been established in apheresis therapy for various glomerular diseases.
Introduction
Since 1975, apheresis therapy has been applied to a wide range of glomerular disorders, with the development of effi cient plasma separation and following reports of its beneficial effect in anti-glomerular basement membrane (GBM) diseases. 1 Since then, new extracorporeal techniques, such as immunoadsorption plasmapheresis (IAPP), doublefi ltration plasmapheresis (DFPP), low-density lipoprotein (LDL) apheresis, and lymphocyte or granulocyte apheresis (LCAP or GCAP) have been developed. 2 In nephrotic syndrome, apheresis therapies have been used to remove pathological factors. Apheresis has been used to remove autoantibodies, immune-complexes, or pathological lymphocytes in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, and in immune-complex diseases such as lupus nephritis.
Glomerular permeability factor(s) derived from T cells may play a crucial role(s) in the protein excretion of nephrotic syndrome, especially in minimal-change nephrotic syndrome (MCNS). 3 Circulating glomerular albumin permeability factor(s) were also detected in patients with native (primary) focal segmental glomerulosclerosis (FSGS) and recurrent FSGS after renal transplantation. 4, 5 In such patients, plasma protein adsorption, using protein A sepharose cartridges 6, 7 or anti-human immunoglobulin affi nity immunoadsorption, 7, 8 plasma exchange (PE), 9 ,10 LDL apheresis, 11 and/or LCAP 12 has been reported to be effective even for steroid-cyclosporin-A (CyA)-resistant cases by removing the glomerular permeability factor(s) in some of these nephrotic patients.
Here, we give an overview of the immunomodulatory effects and clinical evidence of apheresis in various glomerular diseases, especially nephrotic syndrome and severe nephritic syndrome.
Immunomodulation induced by apheresis in glomerular diseases: possible mechanisms
The exact mechanisms by which apheresis provides a benefi t in glomerular diseases are still being investigated. However, possible mechanisms of apheresis in renal diseases are summarized in Table 1 . In addition to the removal of pathological agents such as antibodies, immune-complexes, and/ or immune-associated cells, the removal of proinfl ammatory mediators, including cytokines, chemokines, and complements, and an infl uence on immune systems, including reticuloendothelial function and cellular immunity, have been postulated to contribute to the benefi cial effects of apheresis. In Tcell-mediated autoimmune disorders, including glomerular diseases such as Goodpasture's syndrome, apheresis using LCAP and/or plasmapheresis, such as immunoadsorption by anti-IgG or protein A adsorber columns, affected the Th1/Th2 balance of helper T cells, as assessed by the determination of interleukin (IL)-2, IL-4, and gamma-interferon production in circulating CD4-positive T cells or mononuclear cells. 13, 14 In addition, the infusion of normal plasma may itself have benefi cial effects in some diseases, such as both congenital (familial) and acquired thrombotic thrombocytopenic purpura (TTP, congenital TTP; also called Upshaw-Schulman syndrome), in which the replacement of a defi cient factor, i.e., von Willebrand factor-cleaving protease (ADAMTS-13) may be the principal mechanism of PE, in combination with the removal of circulating inhibitors, defi ned as anti-ADAMTS-13 antibodies, in acquired TTP. 14 
Apheresis techniques for renal diseases
When we perform extracorporeal immunomodulation for glomerular diseases, the most important point is to select the appropriate methods for treating the patients. Current technical aspects of apheresis are shown in Table 2 . In brief, soluble components are treated by standard (whole) PE, fractionated PE (such as DFPP using a plasma separator and fractionator), cryofi ltration, and plasma adsorption that utilizes either protein A, dextran sulfate, tryptophan, or phenylalanine as a ligand. As for cellular components, centrifugation and specifi c adsorption cartridges are applied to separate lymphocytes and/or granulocytes concomitant with activated platelets.
Plasma exchange, DFPP, and IAPP for soluble factors in glomerular diseases
The pathogenicity of anti-GBM antibodies towards the noncollagenous domain in the C-terminus of the alpha 3 and/or 5 chain of type IV collagen that is present in kidney and lung basement membrane has been shown. Anti-GBM disease typically presents as crescentic glomerulonephritis alone or with lung hemorrhage (Goodpasture's syndrome). The titer of circulating anti-GBM antibodies, which antibodies have been detected in more than 90% of patients, 15 compared the effect of PE, with 4 L every 3 days, plus conventional immunosuppressive therapy (prednisolone and cyclophosphamide) to the effect of immunosuppression alone in a randomized controlled trial of 17 patients with anti-GBM nephritis. They found a more rapid disappearance of circulating anti-GBM antibodies and more favorable renal function at the end of the study in the patients treated with PE (serum creatinine level, 4.4+/ −0.6 mg/dl in those with combined therapy vs 9.5+/−0.7 mg/ dl in those with immunosuppression alone; P < 0.05). In addition, the results for more than 250 patients in uncontrolled studies, published over the past three decades, have also suggested a favorable renal outcome in about 40% of patients. However, oliguric patients and those on hemo dialysis before apheresis rarely improved with apheresis treatment. In such patients, apheresis was proposed only if lung hemorrhage was present. The current strategy for anti-GBM disease is to carry out apheresis (such as PE or DFPP) in all patients who are dialysis-independent before the therapy and to carry out apheresis in those with lung complications, even if they have end-stage renal failure.
ANCA-related diseases
The mechanisms by which apheresis is of benefi t for smallvessel vasculitides remain obscure. 16 Recent studies revealed that ANCA itself could induce necrotizing glomerulonephritis in an animal model, and that Th1-type helper Tcell-induced IgG subclasses (IgG1 or IgG1/IgG3) may be related to the disease activity of ANCA-associated vasculitis. Hence, in ANCA-associated diseases, it seems reasonable to remove the circulating ANCA and to alter the Th1/Th2-type helper Tcell balance by extracorporeal immunomodulation therapy. The effectiveness of PE has been reported in some patients with rapidly progressive glomerulonephritis (RPGN), in which ANCA-associated vasculitis is the most common cause. In six randomized controlled trials, [17] [18] [19] [20] [21] [22] there was no statistically signifi cant benefi t from PE in the whole group, including patients with ANCA-associated glomerulonephritis. However, in a previous study, a signifi cant difference was reported in a dialysisdependent group with RPGN and systemic involvement, in which 10 of 11 patients treated by PE and 3 of 8 control patients recovered renal function by 4 weeks. In addition, good outcomes after PE have been reported in patients with lung hemorrhage and severe neurological diseases. The multicenter European MEPEX trial (methylprednisolone pulse therapy versus PE as additional therapy for severe ANCA-associated glomerulonephritis) has attempted to defi ne the role of PE in patients with ANCA-associated vasculitis and an initial creatinine level of more than 500 µmol/l. In this study, PE was a positive predictor of dialysis independence after 12 months for the entire patient group; PE also remained a positive predictor of dialysis independence when patients who were dialysis-dependent at presentation were analyzed separately. 22 These results, supporting a benefi cial role of apheresis in various groups of patients with small-vessel vasculitides, are still from a small number of patients, but it seems that dialysis-dependent patients who have severe systemic diseases or high risks of complications such as infection are the group who may benefi t from PE.
Lupus nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, which commonly involves glomerular disorders. The prognosis of patients with lupus glomerulonephritis, especially proliferative glomerulonephritis, World Health Organization (WHO) class IV or International Society of Nephrology (ISN)/Renal Pathology Society (RPS) 2003 class IV-G and IV-S, is poor, even if they receive immunosuppressive therapy in combination with glucocorticoids and cytotoxic drugs such as cyclophosphamide. Autoantibodies to double-stranded (ds)-DNA and other nuclear components are thought to participate in the initiation and progression of lupus nephritis. Renal injury may result from either the deposition or the in-situ formation of immune-complexes, or from direct injury by pathogenic autoantibodies or cytotoxic infi ltrated cells such as macrophages and T cells. In this regard, the use of apheresis therapy as a specifi c treatment to remove pathologically relevant autoantibodies or circulating cells seems rational. 23 Various apheresis techniques, such as PE; DFPP; or adsorption apheresis, using either protein A, dextran sulfate, tryptophan, or phenylalanine as a ligand, have been explored for the treatment of lupus nephritis. 23 Plasmapheresis therapy has been used, but there have been few controlled clinical observations of its effi cacy. In 1992, Lewis and the Lupus Nephritis Collaborative Study Group 24 carried out a randomized controlled trial comparing a standard-therapy regimen of prednisone and cyclophosphamide (standard therapy) with a regimen of standard therapy plus plasmapheresis in 86 patients with severe lupus nephritis at 14 medical centers. The patients underwent PE three times weekly for 4 weeks. Forty-six patients received standard therapy, and 40 patients received standard therapy plus plasmapheresis. Patients treated with PE had a signifi cantly more rapid reduction of serum concentrations of antibodies against ds-DNA and cryoglobulins. However, treatment with PE plus standard therapy did not improve the clinical outcome in patients with SLE and severe nephritis, as compared with the standard therapy alone. In another study, Wallace et al., 25 in a randomized controlled trial of methylprednisolone pulse/synchronization cyclophosphamide/ apheresis, assessed the effi cacy of synchronization cyclophosphamide, or apheresis, for proliferative lupus nephritis. Eighteen patients with WHO class III or IV renal biopsies and chronicity indices of less than 6 points were prospectively randomized to receive six courses of parenteral cyclophosphamide over 8 months, or apheresis in addition to this therapy. No intergroup comparisons were signifi cant. Thus, this study concluded that the addition of synchronization apheresis to cyclophosphamide therapy did not improve the course of patients with proliferative lupus nephritis. Other trials using adsorption apheresis showed a reduction of autoantibody titers and proteinuria, but these data in patients with lupus nephritis are limited. On the basis of currently available evidence, although apheresis therapy may modify the underlying pathogenic mechanisms in severe proliferative lupus nephritis, PE or other apheresis therapy offers no clear clinical benefi t over conventional immunosuppressive therapy in these patients. However, apheresis therapy, because of its rapid removal of circulating pathological factors, does seem promising in individual patients with acute life-threatening diseases such as catastrophic anti-phospholipid syndrome (CAPS), or those who are resistant to standard drug therapy.
Nephrotic syndrome
Proteinuria in patients with MCNS and FSGS is speculated to be caused by damage to the negatively charged barrier of the glomerular capillary walls by some cationic substance. 26 Certain substances derived from serum, urine, or lymphocytes in patients with MCNS have been reported as being responsible for the damage. 3 In addition, abnormal T-cell function was also proposed as a pathogenic factor.
27,28
Savin's group (Artero et al., 9 Feld et al., 10 and Sharma et al. 28 ) reported that plasmapheresis could diminish proteinuria and stabilize renal function in some patients with steroid-resistant idiopathic FSGS, suggesting that FSGS has some different local or systemic factor(s) unrelated to glomerular permeability. In addition, a recent prospective trial in ten patients at high-risk for FSGS recurrence, because of rapid progression to renal failure (n = 4) or prior transplant recurrence of FSGS (n = 6), underwent a course of eight PE treatments in the perioperative period. Seven patients, including all four with fi rst grafts and three of the six with prior recurrence, were free of recurrence at follow-up (238-1258 days). 29 Dantal et al. 6, 8 have reported that an active factor binds to protein A in FSGS; this factor was thought to be immunoglobulin, an immunoglobulin fragment or a protein binding to Fc chains, such as a complement component, transforming growth factor-β or another Ig-binding protein. Bosch and Wendler 30 summarized recent studies providing evidence that patients with recurrent FSGS after renal transplantation and those with primary FSGS can profi t from PE or immunoadsorption. They concluded that the indications for performing extracorporeal plasma therapy for recurrent FSGS would at best meet category II (accepted supportive therapy) according to the guidelines of the American Society for Apheresis, but for primary FSGS, the indications would be category III (confl icting results, anecdotal reports).
The presence of hyperlipidemia, especially with LDL, is an important factor in the outcome of patients with steroidresistant nephrotic syndrome. Muso et al. 11 fi rst reported the effect of LDL apheresis in steroid-resistant nephrotic syndrome, in six patients with FSGS, one with MCNS, and one with membranous nephropathy (MN) and FSGS. The LDL apheresis, was carried out 2-13 times (mean, 7.3) for one nephrotic episode, and, combined with steroid pulse therapy, led to rapid amelioration of the hyperlipidemia. Moreover, more than 50% reduction of proteinuria occurred (less than 3.5 g/day) in six nephrotic episodes (fi ve patients). A signifi cant elevation of serum albumin (more than 3.0 g/dl) was also obtained in fi ve of these episodes. In another study, Yokoyama et al. 31 found that LDL apheresis improved the response to steroid therapy in patients with FSGS associated with nephrotic syndrome resistant to steroid, and that only electron microscopy was able to detect histological recovery in the patients who showed a decrease of proteinuria after LDL apheresis. They 32 also reported a patient with primary FSGS in whom complete remission of the nephrotic state was achieved with LDL apheresis alone. In the only prospective study of LDL apheresis reported by Stenvinkel and a Swedish group, 33 the LDL apheresis caused a rapid 30%-40% decrease in serum cholesterol and plasma Lp (a) levels in patients with nephrotic syndrome. Their prospective study also suggested that short-term LDL apheresis might increase serum albumin levels in nephrotic patients. Although the level of evidence is still low, it is expected that the rapid improvement of hypercholesterolemia by LDL apheresis will provide more rapid relief from the nephrotic state than immunosuppressive therapy alone in steroid-resistant nephrotic syndrome, especially primary FSGS.
LCAP or GCAP for glomerular diseases, nephrotic syndrome, and vasculitis
In general, macrophages, cytotoxic cells, and Th1-type helper T cells play a central role in the glomerular injury of crescentic glomerulonephritis. In addition, glomerular permeability factor(s) derived from T cells may play a crucial role(s) in the protein excretion of nephrotic syndrome, especially MCNS and FSGS.
3 Also, recent reviews by Takenaka 34 and Bosch 35 have reported that the removal of these pathogenic cells by lymphocytapheresis is effective in the treatment of autoimmune diseases or lymphocyte abnormalities, such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease.
Nephrotic syndrome
After the performance of LCAP in patients with nephrotic syndrome, neither the total number and population of peripheral blood WBC nor the CD4/CD8 ratio changed; how-ever, in the response group, the total number of lymphocytes, T cells, B cells, and HLA-DR-positive activated T cells decreased signifi cantly. In the nonresponse group after LCAP, there was no alteration of lymphocyte subsets. No adverse effects were recorded during or after LCAP in any patients. Proteinuria tended to decrease at 2 weeks post-treatment (8.2 ± 1.8 g/day before and 5.6 ± 1.3 g/day at 2 weeks). Especially, patients with MCNS or FSGS showed good response to LCAP, resulting in a dramatic decrease of daily proteinuria. The urinary protein/creatinine ratio also decreased, by −30% to −94% in these patients. Finally, complete or partial remission (proteinuria <1.0 g/day) was seen in patients treated by LCAP, followed by immunosuppressive or supportive therapy. During LCAP, 12 the serum levels of immunoglobulins, complements, and lipids showed very little change, even in the response group, suggesting that the mechanism of LCAP may be different from the mechanisms of plasma protein adsorption using protein A sepharose cartridges, 6, 7 anti-human immunoglobulin affi nity immunoadsorption, 7, 8 or LDL apheresis, 11 as previously described.
Crescentic glomerulonephritis with ANCA-associated vasculitis or IgA nephropathy Furuta et al. 36 investigated the effi cacy of LCAP, in comparison with steroid-pulse treatment, for the treatment of RPGN. They enrolled 24 patients with biopsy-proven RPGN in a prospective randomized study. The 12 patients in the LCAP group completed nine LCAP sessions in 3 consecutive weeks, performed with a Cellsorba cartridge (CS-120, Asahi Kasei Medical, Tokyo, Japan). The other 12 patients (controls) received 1 g methylprednisolone for 3 consecutive days in each of 3 consecutive weeks. All patients received prednisolone (20 mg/day) and cyclophosphamide (50 mg/day). In the LCAP group 7 patients had IgA nephropathy and 5 had pauci-immune nephropathy; and in the steroid-pulse group, 5 patients had IgA nephropathy and 7 had pauci-immune nephropathy. The LCAP group showed signifi cant improvements in renal function and lessening of proteinuria. In the LCAP group, The ratio of CD4 to CD8 cells showed no signifi cant change after the treatment, but the CD14/CD3 ratio was substantially lower, suggesting that this maneuver removed mainly CD8 and CD14 cells. Furuta et al. 36 concluded that LCAP was more effective than steroid-pulse treatment for the reduction of the glomerular injury due to RPGN, as an effect of its selective removal of CD8 and CD14 cells. Hasegawa et al. 37 also reported the effi cacy of cytapheresis for the treatment of RPGN caused by myeloperoxidase-ANCA associated vasculitis, in a comparison of a cytapheresis group and a steroid-pulse group. In their study, in the 10 patients in the cytapheresis group, 5 patients were treated by GCAP with the Adacolumn (JIMRO Co., Ltd, Takasaki, Japan) and the other 5 patients received LCAP with the Cellsorba cartridge. In the cytapheresis group, the mortality rate caused by infection was reduced at 1 year after treatment.
Conclusions
In terms of immunomodulation, apheresis therapies not only accelerate the disappearance of circulating pathogenic factors such as autoantibodies, circulating permeability factor(s), and T cells, but they are also able to modulate the immune response in the background of glomerular diseases (see Table 3 for evidence of the effi cacy of various apheresis therapies in glomerular diseases). It seems reasonable to conclude that the removal of circulating pathogenic factors by apheresis is an effective adjunct to conventional therapy in severe glomerular diseases. In future, prospective randomized trials with appropriate statistical evaluation will defi ne the exact effects of apheresis in relation to the outcome of each glomerular disease.
